Table 2.
Baseline features、clinical treatments and outcomes of MEF2D positive B-ALL patients
| N | Age | Sex | MEF2D type | Extramedullary infiltration | Induction therapy |
Response | Status post-induction | Consolidation therapy |
Response | Status post-consolidation | CR achieved within 3 months | Immunotherapy | Status after Immunotherapy | Status before HSCT | HSCT | Outcome, OS(m) | The cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42 | F | MEF2D::HNRNPUL1 | N | IVP | CR | MRD(-), MEF2D(-) | Hyper cvad b | CR | MRD(-), MEF2D(-) | Y | Blinatumomab | MRD(-), MEF2D(-) | MRD(-), MEF2D(-) | Y | Live, 14 | / |
| 2 | 33 | F | MEF2D::BCL9 | N | IVLP | PR | MRD(+), MEF2D(+) | CAV | CR | MRD(-), MEF2D(+) | N | Blinatumomab | MRD(+), MEF2D(+) | / | N | Die, 7 | relapse |
| 3 | 37 | F | MEF2D::ARID1B | Y | VP | CR | MRD(-), MEF2D(-) | HD-Arac | CR | MRD(-), MEF2D(+) | Y | CD19/CD22 CART+Blinatumomab | MRD(-), MEF2D(+) | MRD(-), MEF2D(+) | Y | Die, 24 | relapse |
| 4 | 48 | F | MEF2D::BCL9 | N | IVP | CR | MRD(+), MEF2D(+) | HD-Arac + L-Asp | NR | MRD(+), MEF2D(+) | N | / | / | / | N | Die, 5 | relapse |
| 5 | 40 | M | MEF2D::BCL9 | Y | Hyper cvad a | CR | MRD(-), MEF2D(-) | Hyper cvad b | NR | MRD(+), MEF2D(+) | N | Blinatumomab | MRD(+), MEF2D(+) | MRD(+), MEF2D(+) | Y | Die, 16 | relapse |
| 6 | 47 | F | MEF2D::HNRNPUL1 | N | CIVP | CR | MRD(-), MEF2D(+) | CMOP | NR | MRD(+), MEF2D(+) | N |
CD19 CART |
MRD(-), MEF2D(+) | MRD(-), MEF2D(+) | Y | Die, 21 | CMV viremia |
| 7 | 34 | F | MEF2D::HNRNPUL1 | N | CIVP | CR | MRD(-), MEF2D(-) | CAM | CR | MRD(-), MEF2D(-) | Y | Blinatumomab | MRD(-), MEF2D(-) | MRD(-), MEF2D(-) | Y | Live, 8 | / |
| 8 | 37 | F | MEF2D::BCL9 | N | IVP | CR | MRD(-), MEF2D(-) | CAM | CR | MRD(-), MEF2D(-) | Y | Blinatumomab | MRD(-), MEF2D(-) | / | N | Live, 7 | / |
| 9 | 17 | M | MEF2D::BCL9 | Y | VDLP | CR | MRD(-), MEF2D(+) | CIVP | NR | MRD(+), MEF2D(+) | N | Blinatumomab | MRD(+), MEF2D(+) | / | N | Die, 8 | relapse |
| 10 | 34 | M | MEF2D::HNRNPM | N | CIVLP | CR | MRD(-), MEF2D(+) | CIVP | PR | MRD(+), MEF2D(+) | N | CD19/CD22 CART | MRD(-), MEF2D(+) | MRD(-), MEF2D(+) | Y | Die, 12 | septicemia |
| 11 | 16 | F | MEF2D::BCL9 | N | VDLP | CR | MRD(-), MEF2D(+) | CAM | CR | MRD(-), MEF2D(+) | Y | CD19/CD22 CART | MRD(-), MEF2D(+) | MRD(-), MEF2D(+) | Y | Die, 26 | relapse |
| 12 | 46 | M | MEF2D::HNRNPUL1 | N | Hyper cvad a | CR | MRD(-), MEF2D(+) | Hyper cvad b | CR | MRD(-), MEF2D(+) | Y | Blinatumomab | MRD(-), MEF2D(+) | MRD(-), MEF2D(+) | Y | Live, 30 | / |
| 13 | 31 | M | MEF2D::BCL9 | N | VDP | PR | MRD(+), MEF2D(+) | VA | CR | MRD(-), MEF2D(+) | Y | CD19/CD22 CART | MRD(-), MEF2D(-) | MRD(-), MEF2D(-) | Y | Live, 34 | / |
| 14 | 18 | F | MEF2D::HNRNPUL1 | Y | IVLP | CR | MRD(-), MEF2D(+) | HD-Arac + L-Asp | NR | MRD(+), MEF2D(+) | N | / | / | MRD(-), MEF2D(+) | Y | Die, 16 | relapse |
| 15 | 49 | F | MEF2D::BCL9 | Y | IVP | CR | MRD(-), MEF2D(+) | HD-Arac + L-Asp | CR | MRD(-), MEF2D(+) | Y | Blinatumomab | MRD(+), MEF2D(+) | / | N | Die, 7 |
Relapse+ septicemia |
Note: IVP ± CTX ± L-Asp:idarubicin+vincristine+prednisone ± cyclophosphamide ± L-asparaginase; Hyper-cvad a:cyclophosphamide+vincristine+doxorubicin+dexamethasone; Hyper-cvad b:cytarabine+methotrexate; HD-Arac:High-dose cytarabine; CAM:cyclophosphamide+doxorubicin+methotrexate; CMOP:cyclophosphamide+methotrexate+vincristine+prednisone; CAV: cladribine+cytarabine+venetoclax; VA:venetoclax+azacitidine; CR:complete remission; PR:partial remission; NR:No Remission;